Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma
{{output}}
Background and objective: A population pharmacokinetics (PopPK) model was developed for elranatamab, a bispecific antibody targeting both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3), to characterize th... ...
